

Fig. 2 Activities towards glycoamino acid **4** of a range of novel proteases created through the *in situ* chemical modification of S166C. Novel proteases and their creation are shown in blue, corresponding modifications of the enzymes to alter activity shown in red and the reaction catalyzed and used as a screen shown in black.

groups. However, after a survey of a range of methods, deprotection was pleasingly achieved using hydrazine monohydrate in 79% methanol resulting in deprotected *p*-nitroanilide glycoamino acid **4**.

Armed with this useful chromophoric probe for our desired enzyme activity we surveyed various protease catalysts. Potential structural variation through chemical modification in the active site of SBL is so vast that a combinatorial approach to enzyme screening and preparation was taken to identify the best CMMs for this transformation. The method developed by Plettner *et al.*¹⁷ took advantage of the quantitative and rapid reaction of methanethiosulfonate (MTS) reagents with free protein cysteine residues (inset in Fig. 2).¹⁸ Modifications of cysteine mutant SBL-S166C (Fig. 2) were carried out on a microscale in a 96-well plate and were monitored using Ellman's reagent.¹⁹ Estimations for $k_{\text{cat}}/K_{\text{M}}$ were then obtained directly from the rate of *p*NA released from **4** ($\epsilon_{414} = 2502 \text{ M}^{-1} \text{ cm}^{-1}$) using the limiting case of the Michaelis–Menten equation at low substrate concentrations of 0.1 mM using these modified enzymes. The results are summarised in Fig. 2.

Promising catalysts, S166C-**a**, -**c**, -**e**, -**g**, were selected for more detailed evaluation on the basis of these results and previous significant substrate specificity broadening by polar aromatics²⁰ and charged polar patches.⁷ Larger scale modification reactions in aqueous buffer were rapid and quantitative, as judged by titration of free thiols with Ellman's reagent.¹⁹ Mass spectrometry was used to confirm CMM structure. The precise effects of the modifications to SBL were assessed by full Michaelis–Menten kinetics for the hydrolysis of **8** at pH 8.6 over a range of concentrations (0.02–8.0 mM) and the results are summarised in Table 1.

Table 1 Catalytic activity for the hydrolysis of glycoamino acid **4** by selected modified proteases


Enzyme	Est. $k_{\text{cat}}/K_{\text{M}}/\text{M}^{-1} \text{ s}^{-1}$	K_{M}/M	$k_{\text{cat}}/\text{s}^{-1}$	$k_{\text{cat}}/K_{\text{M}}/\text{M}^{-1} \text{ s}^{-1}$
WT	3.62	0.0023	0.007	3.04
S166C- g	6.79	0.0036	0.008	2.16
S166C- e	7.39	0.0020	0.009	4.47
S166C- a	14.6	0.0014	0.0005	0.39 ^a
S166C- c	33.2	0.0054	0.008	1.51 ^a

^a Large difference from est. may be due to 'low substrate approximation' breakdown.

Having identified the modifications which gave the most desirable catalytic activity, peptide ligation reactions were attempted with the glycoamino acid methyl ester substrate **7** as a suitable acyl donor. The serine methyl ester was successfully prepared using thionyl chloride and methanol.²¹ Glycosylation using the same conditions as for **3** yielded **6**, followed by hydrazine deprotection to afford **7** (Scheme 1).

With glycylamide as an acyl acceptor, the majority of the modifications showed an increase in efficiency compared to the wild type, with S166C-**e** yielding a pleasing 90% glycopeptide. Excitingly, using S166C-**e**, substrate specificity was also broadened to allow β -alaninamide and γ -butyricamide as acyl acceptors, albeit in lower yields than for glycylamide (Table 2). These are the first direct ligations of hexosyl amino acids.

Application to potentially therapeutic targets was also investigated. Compound **11** is an analogue of known active glycolipid galactosyl–ceramide mimics that are able to inhibit HIV uptake and infection of CD4-negative cells.²² The desired glycolipid analogue **11** was formed under catalysis by S166C-**e** in 35% yield (Scheme 3).




Scheme 2 (i) Enzyme (0.1 mol%), Et₃N, DMF–H₂O (1 : 1). Acyl donor : acceptor, 1 : 3.

Table 2 Results from enzyme catalysed ligation reactions according to Scheme 2 with amino acid acyl acceptors

Amino acid	n	Product	Yield (%) ^a (5 days) S166C			
			WT	-g	-e	-c
Gly–NH ₂ ·HCl	1	Glc–Z–Ser–Gly–NH ₂ 8	60	73	90	20
β-Ala–NH ₂ ·HCl	2	Glc–Z–Ser–β-Ala–NH ₂ 9	22	— ^b	53	— ^b
γ-Aba–NH ₂ ·HCl	3	Glc–Z–Ser–γ-Aba–NH ₂ 10	15	— ^b	36	— ^b

^a Yield based on compound **7**. ^b Ligation not attempted.



Scheme 3 Synthesis of glycolipid analogue *via* direct enzymatic ligation.

In summary, we have shown that combined site-directed mutagenesis and chemical modification can be used to broaden the substrate specificity of SBL and was utilised in the first direct ligations of hexosyl amino acids. A triamino substituent in the S₁ pocket leads to the greatest substrate broadening and was used in the synthesis of various glycopeptides and analogues of compounds showing anti-HIV activity.

We thank the Leverhulme Trust for funding.

Katie J. Doores and Benjamin G. Davis*

Department of Chemistry, University of Oxford, Chemistry Research Laboratory, Mansfield Road, Oxford, UK OX1 3TA.
E-mail: ben.davis@chem.ox.ac.uk; Fax: + 44 (0)1865 285002;
Tel: + 44 (0)1865 275652

Notes and references

- B. G. Davis, *Chem. Rev.*, 2002, **102**, 579.
- C.-H. Wong and G. M. Whitesides, *Enzymes in Synthetic Organic Chemistry*, Pergamon, Oxford, 1994.
- C.-H. Wong, M. Schuster, P. Wang and P. Sears, *J. Am. Chem. Soc.*, 1993, **115**, 5893.
- K. Witte, O. Seitz and C.-H. Wong, *J. Am. Chem. Soc.*, 1998, **120**, 1979.
- K. Witte, P. Sears, R. Martin and C.-H. Wong, *J. Am. Chem. Soc.*, 1997, **119**, 2114.
- Z. Machova, R. Eggelkraut-Gottanka, N. Wehofsky, F. Bordusa and A. Beck-Sickinger, *Angew. Chem., Int. Ed.*, 2003, **42**, 4916.
- K. Matsumoto, B. G. Davis and J. Jones, *Chem. Eur. J.*, 2002, **8**, 4129.
- K. Khumtaveeporn, G. DeSantis and J. B. Jones, *Tetrahedron: Asymmetry*, 1999, **10**, 2563.
- A. Scheurer, P. Mosset, W. Bauer and R. W. Saalfrank, *Eur. J. Org. Chem.*, 2001, **16**, 3067.
- D. Rijkers, H. Adams, H. C. Hemker and G. Tesser, *Tetrahedron*, 1995, **51**, 11235.
- Y. Bilokin, A. Melman, V. Niddam, B. Benhamu and M. Bachi, *Tetrahedron*, 2000, **56**, 3425.
- C. Taylor, *Tetrahedron*, 1998, **54**, 11317.
- K. P. R. Kartha, L. Ballell, J. Bilke, M. McNeil and R. A. Field, *J. Chem. Soc., Perkin Trans. 1*, 2001, 770.
- R. R. Schmidt, *Angew. Chem., Int. Ed. Engl.*, 1986, **25**, 212.
- G. Grundler and R. R. Schmidt, *Liebigs Ann. Chem.*, 1984, 1826.
- P. Sjolín and J. Kihlberg, *Tetrahedron Lett.*, 2000, **41**, 4435.
- E. Plettner, K. Khumtaveeporn, X. Shang and J. Jones, *Bioorg. Med. Chem. Lett.*, 1998, **8**, 2291.
- T. Bruice and G. Kenyon, *J. Protein. Chem.*, 1982, **1**, 47.
- G. Ellman, K. Courtney, V. Andres and R. Featherstone, *Biochem. Pharmacol.*, 1961, **7**, 88.
- K. Khumtaveeporn, A. Ullmann, K. Matsumoto, B. G. Davis and J. Jones, *Tetrahedron: Asymmetry*, 2001, **12**, 249.
- D.-R. Hwang, P. Helquist and M. Shekhani, *J. Org. Chem.*, 1985, **50**, 1265.
- B. Faroux-Corlay, L. Clary, C. Gadrás, D. Hammache, J. Greiner, C. Santaella, A.-M. Aubertin, P. Vierling and J. Fantini, *Carbohydr. Res.*, 2000, **327**, 223.